Physician profile
Richard Centar
NPI 1285679282
$3,789.68
in general payments reported to CMS, 2019-2025
14 companies · $71.93 in 2025
The $71.93 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,581 · 2020: $138 · 2021: $494 · 2022: $280 · 2023: $225 · 2025: $71.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,403.92 | 2019-2025 | Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $250.38 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $191.10 | 2019-2023 | Acuvue |
| Biotissue Holdings INC. | $184.00 | 2019-2022 | |
| Maculogix, INC. | $147.23 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $146.63 | 2019-2023 | Cequa |
| Bausch & Lomb Americas INC. | $117.97 | 2022-2023 | Infuse |
| Oyster Point Pharma, INC. | $108.50 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $107.48 | 2020-2023 | |
| Allergan, INC. | $49.88 | 2021 | |
| Kala Pharmaceuticals, INC. | $32.05 | 2021 | |
| Ivantis, INC | $20.67 | 2021 | |
| Shire North American Group INC | $18.49 | 2019 | |
| Coopervision INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Centar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.